Positive Phase 3 Data for Tarcocimab

Show Description +

Dr. Wykoff shares first-time results of the phase 3 DAYBREAK trial, which showed that 54% of patients with wet AMD treated with tarcocimab tedromer (Zenkuda, Kodiak) achieved a 6-month dosing interval.

Posted: 10/15/2026

Keywords:

tarcocimab

•

DAYBREAK

•

Clinical Trials

•

Age-Related Macular Degeneration (AMD)

•

Wet AMD

•

tarcocimab tedromer

•

Zenkuda

•

Kodiak

•

dosing

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Positive Phase 3 Data for Tarcocimab
Uploaded: 2026-10-15T19:09:10+00:00
Description: Dr. Wykoff shares first-time results of the phase 3 DAYBREAK trial, which showed that 54% of patients with wet AMD treated with tarcocimab tedromer (Zenkuda, Kodiak) achieved a 6-month dosing interval.